Durect up on FDA's 'breakthrough therapy' tag for liver disease treatment

DURECT

21/05/2024 15:17

** Shares of drugmaker Durect Corp  DRRX.O  rise 3.8% to
$1.1 
    ** U.S. FDA has granted "breakthrough therapy" designation
(BTD) to DRRX's treatment for patients with severe
alcohol-associated hepatitis (AH)
    ** AH is an acute form of liver disease associated with
long-term heavy alcohol intake, often following a recent period
of increased consumption
    ** Company plans to confirm the efficacy and safety of the
treatment candidate, larsucosterol, in a registrational
late-stage trial 
    ** BTD is meant to speed up the development and review of
drugs to treat a serious condition or unmet medical need 
    ** Including session's gain, stock up more than 80% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))